Kardigan develops medicines to prevent and treat cardiovascular disease. It focuses on discovering and developing multiple cardiovascular therapies at a rapid pace, using deep expertise in heart-health drug development to move candidates from research toward commercialization. Their product approach centers on creating medicines that address heart disease more effectively and earlier in the disease process. Kardigan differentiates itself through a leadership team of seasoned biopharma veterans and a commitment to modernizing how cardiovascular drugs are discovered and developed, aiming to bring therapies to patients faster and more efficiently. The company’s goal is to reduce the global burden of cardiovascular disease by providing safe, effective medicines that prevent progression or cure conditions related to heart health.
Company Size
201-500
Company Stage
IPO
Headquarters
West Windsor Township, New Jersey
Founded
2023
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?